Corcept Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Corcept Therapeutics Incorporated
CORT Stock  USD 38.20  3.40  9.77%   
Analyzing historical trends in various income statement and balance sheet accounts from Corcept Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Corcept Therapeutics' valuation are summarized below:
Gross Profit
727.8 M
Profit Margin
0.1432
Market Capitalization
4 B
Enterprise Value Revenue
4.3785
Revenue
741.2 M
There are currently one hundred twenty fundamental signals for Corcept Therapeutics Incorporated that can be evaluated and compared over time across rivals. All traders should validate Corcept Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 3.2 B in 2026. Enterprise Value is likely to gain to about 3.1 B in 2026

Corcept Therapeutics Total Revenue

815.11 Million

Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 194.4 M or Research Development of 298.1 M, as well as many indicators such as Price To Sales Ratio of 8.42, Dividend Yield of 0.0 or PTB Ratio of 7.23. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Corcept Stock
Check out the analysis of Corcept Therapeutics Correlation against competitors.

Corcept Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1 B966.6 M372.1 M
Slightly volatile
Total Current Liabilities170 M161.9 M53 M
Slightly volatile
Accounts Payable18.6 M17.7 M8.1 M
Slightly volatile
Cash75.7 M146.8 M103.1 M
Slightly volatile
Other Current Assets21.5 M20.4 M8.1 M
Slightly volatile
Total Liabilities194.4 M185.1 M66.1 M
Slightly volatile
Common Stock88.6 K156.4 K109.6 K
Slightly volatile
Property Plant Equipment2.1 M2 M903.8 K
Slightly volatile
Other Assets93.5 M89.1 M45.3 M
Slightly volatile
Common Stock Shares Outstanding84.9 M130.5 M105.1 M
Slightly volatile
Liabilities And Stockholders Equity1 B966.6 M373.5 M
Slightly volatile
Short and Long Term Debt Total10.2 M8 M12.6 M
Slightly volatile
Property Plant And Equipment Net9.7 M9.2 M2.3 M
Slightly volatile
Non Current Assets Total445.5 M424.3 M115.6 M
Slightly volatile
Non Currrent Assets Other12.3 M11.7 M8.2 M
Slightly volatile
Cash And Short Term Investments462.9 M440.8 M217 M
Slightly volatile
Common Stock Total Equity87.7 K146.1 K107.8 K
Slightly volatile
Property Plant And Equipment Gross9.7 M9.2 M2.3 M
Slightly volatile
Total Current Assets569.5 M542.3 M257.1 M
Slightly volatile
Current Deferred Revenue22.3 M21.2 M8.8 M
Slightly volatile
Short Term Debt905.7 K953.4 K3.6 M
Slightly volatile
Capital Surpluse426.4 M680.1 M434.6 M
Slightly volatile
Net Receivables70.1 M66.8 M26 M
Slightly volatile
Long Term Debt Total19.1 M11.3 M17.5 M
Slightly volatile
Short and Long Term Debt14.3 M16.9 M13.2 M
Slightly volatile
Net Invested Capital471 M781.5 M353.8 M
Slightly volatile
Net Working Capital319.8 M380.5 M217 M
Slightly volatile
Deferred Long Term Asset Charges61.4 M69 M75.3 M
Slightly volatile
Other Liabilities11 M10.5 M3.1 M
Slightly volatile
Capital Stock139.2 K156.4 K124.6 K
Slightly volatile
Non Current Liabilities Other349.7 K368.1 K452.5 K
Pretty Stable
Capital Lease Obligations8.4 M8 M3.7 M
Slightly volatile

Corcept Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative194.4 M252.3 M101.3 M
Slightly volatile
Research Development298.1 M283.9 M99.5 M
Slightly volatile
Other Operating Expenses649.7 M618.8 M218.3 M
Slightly volatile
Total Operating Expenses636.6 M606.3 M213.8 M
Slightly volatile
Depreciation And Amortization802.1 K1.5 M941.9 K
Slightly volatile
Selling And Marketing Expenses3.6 B4 B4.4 B
Slightly volatile
Interest Income29.6 M28.2 M7.9 M
Slightly volatile
Reconciled Depreciation2 M1.5 M1.1 M
Slightly volatile

Corcept Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures1.9 M2 M633.2 K
Slightly volatile
End Period Cash Flow154.2 M146.8 M71.2 M
Slightly volatile
Begin Period Cash Flow163.7 M155.9 M66.2 M
Slightly volatile
Depreciation892 K1.5 M1.1 M
Slightly volatile
Stock Based Compensation77.8 M55.2 M121.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.428.8618.5304
Slightly volatile
Days Sales Outstanding44.6333.5642.8536
Slightly volatile
Stock Based Compensation To Revenue0.09930.10.4293
Slightly volatile
Capex To Depreciation1.781.875.6264
Slightly volatile
EV To Sales8.228.6612.7795
Slightly volatile
Inventory Turnover0.830.790.4791
Slightly volatile
Days Of Inventory On Hand4554791.4 K
Slightly volatile
Payables Turnover0.430.640.482
Slightly volatile
Sales General And Administrative To Revenue192182190
Slightly volatile
Research And Ddevelopement To Revenue0.40.425.0598
Slightly volatile
Capex To Revenue0.00350.00370.2711
Slightly volatile
Cash Per Share3.513.342.7538
Slightly volatile
Days Payables Outstanding5635933.5 K
Slightly volatile
Current Ratio2.863.0211.0048
Very volatile
Receivables Turnover7.9811.269.4613
Slightly volatile
Graham Number6.5312.745.7329
Slightly volatile
Capex Per Share0.0230.02420.3379
Slightly volatile
Revenue Per Share6.185.892.4117
Slightly volatile
Interest Debt Per Share0.03380.06050.0542
Slightly volatile
Debt To Assets0.00710.00740.0599
Slightly volatile
Operating Cycle4875121.4 K
Slightly volatile
Days Of Payables Outstanding5635933.5 K
Slightly volatile
Ebt Per Ebit1.291.3658.0161
Slightly volatile
Long Term Debt To Capitalization1.11.040.9517
Slightly volatile
Total Debt To Capitalization0.00860.00910.1576
Slightly volatile
Quick Ratio2.792.9410.6091
Very volatile
Net Income Per E B T1.021.01.4741
Slightly volatile
Cash Ratio0.780.829.3399
Very volatile
Days Of Inventory Outstanding4554791.4 K
Slightly volatile
Days Of Sales Outstanding44.6333.5642.8536
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.631.141.4882
Slightly volatile
Fixed Asset Turnover72.0375.82287
Slightly volatile
Debt Ratio0.00710.00740.0599
Slightly volatile
Price Sales Ratio8.428.8618.5304
Slightly volatile
Asset Turnover0.430.720.6088
Slightly volatile
Gross Profit Margin0.780.890.962
Slightly volatile

Corcept Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.2 B3 B2.1 B
Slightly volatile
Enterprise Value3.1 B2.9 B2 B
Slightly volatile

Corcept Fundamental Market Drivers

Forward Price Earnings15.9236
Cash And Short Term Investments383.3 M

Corcept Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Corcept Therapeutics Financial Statements

Corcept Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Corcept Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corcept Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.2 M22.3 M
Total Revenue776.3 M815.1 M
Cost Of Revenue9.8 M5.8 M
Stock Based Compensation To Revenue 0.10  0.10 
Sales General And Administrative To Revenue 182.39  191.51 
Research And Ddevelopement To Revenue 0.42  0.40 
Revenue Per Share 5.89  6.18 
Ebit Per Revenue 0.18  0.19 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY